TheraRadar
← Back
Data updated: Jun 28, 2026

SUPERPHARM

Generics

SUPERPHARM is a generic drug manufacturer focused on Cardiovascular, Gastroenterology, Dermatology.

1981
Since
44
Drugs
-
Trials
0
New Drugs (2yr)

SUPERPHARM's Key Drugs

SUPERPHARM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

SUPERPHARM's Recent FDA Approvals

New NDA/BLA approvals for SUPERPHARM over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SUPERPHARM's Therapeutic Areas

SUPERPHARM's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Gastroenterology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 33%
2 drugs
Gastroenterology 17%
1 drugs
Dermatology 17%
1 drugs
Neurology 17%
1 drugs
Infectious Disease 17%
1 drugs

SUPERPHARM Pipeline Snapshot

Active clinical trials for SUPERPHARM across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling